Hemodynamic and proteolytic effects of intravenous injection of purified human plasma kallikrein.
To investigate the precise hemodynamic effects of purified human plasma kallikrein, small doses (0.3 U/kg) of this proteolytic enzyme were infused over 10 s in five pigs. Hemodynamic performance was evaluated by means of a Swan-Ganz catheter, and parameters of the plasma kallikrein-kinin, coagulation, and fibrinolytic systems were determined by means of chromogenic peptide substrate assays. The infusions of plasma kallikrein were followed by rapid decreases in mean arterial pressure (to 43 +/- 2% of baseline values) and increases in cardiac output (to 145 +/- 6% of baseline values), accounting for marked decreases in systemic vascular resistance, to 28 +/- 1% of initial values. Heart rate, mean pulmonary arterial, central venous, and pulmonary capillary wedge pressures did not change after the injection. Pulmonary vascular resistance decreased to 69 +/- 3% of baseline values. The hemodynamic changes gradually normalized during the following 10 min. Functional levels of prekallikrein, kallikrein, kallikrein inhibition, prothrombin, antithrombin III, plasmin, and antiplasmin were not affected by the injection or the resulting hemodynamic changes; the hematocrit and the number of circulating leukocytes or platelets were also unaffected.
Naess
F
F
Department of Surgery, Ullevål Hospital, University of Oslo, Norway.
Roeise
O
O
Johansen
H T
HT
Stadaas
J O
JO
Aasen
A O
AO
D000818:Animals; D004591:Electrophoresis, Polyacrylamide Gel; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007275:Injections, Intravenous; D007610:Kallikreins / Q000097:blood / Q000494:pharmacology*; D010447:Peptide Hydrolases / Q000378:metabolism*; D013552:Swine
D010447:Peptide Hydrolases; D007610:Kallikreins